• Brian Spoelhof, Salia Farrokh, and Lucia Rivera-Lara.
• Department of Pharmacy, Lahey Hospital and Medical Center, Burlington, MA, USA. Brian.Spoelhof@lahey.edu.
• Neurocrit Care. 2017 Oct 1; 27 (2): 287-296.

AbstractDrug-drug interactions (DDIs) are common and avoidable complications that are associated with poor patient outcomes. Neurocritical care patients may be at particular risk for DDIs due to alterations in pharmacokinetic profiles and exposure to medications with a high DDI risk. This review describes the principles of DDI pharmacology, common and severe DDIs in Neurocritical care, and recommendations to minimize adverse outcomes. A review of published literature was performed using PubMed by searching for 'Drug Interaction' and several high DDI risk and common neurocritical care medications. Key medication classes included anticoagulants, antimicrobials, antiepileptics, antihypertensives, sedatives, and selective serotonin reuptake inhibitors. Additional literature was also reviewed to determine the risk in neurocritical care and potential therapeutic alternatives. Clinicians should be aware of interactions in this setting, the long-term complications, and therapeutic alternatives.

30 keywords...

hide…